I Am Bhojpuriya

Category: Business

  • Corporate Professionals managing to acquire 26% stake in Advik Capital for Rs 23.75 cr – Primex News Network

    Corporate Professionals managing to acquire 26% stake in Advik Capital for Rs 23.75 cr – Primex News Network

    New Delhi (India), May 20: Corporate Professionals Capital Private Limited is managing to acquire a significant stake in Advik Capital Limited (ACL), the company said in a regulatory filing on 18th May.

    According to the company filing, Corporate professionals managed to buy 5,72,50,253 equity shares with a face value of Re 1 each at a price of Rs 4.15 apiece amounting to Rs 23,75,88,550.

    The deal aggregates to 26 percent paid up equity share capital of the company. The Offer Price will be paid in cash, in accordance with the provisions of Regulation of the SEBI (SAST) Regulations.

    The filing also clarified that the purchase has been made on behalf of Mr. Vikas Garg and Ms Seema Garg (termed as Acquirers); and Ms Sukriti Garg (person acting in concert or ‘PAC’).

    Incorporated in year 1985, Advik Capital Limited is a non-banking finance company (NBFC) registered with the Reserve Bank of India (RBI).

    Mr. Virender Kumar Agarwal and Mr. Shakul Kumar Agarwal, the current members of the promoter and promoter group of the Advik Capital to sell their shares constituting 7.89 percent stake in the company, which triggered the open offer.

    On May 18, 2022, the Acquirers have entered into the special purchase agreement (SPA) with the sellers of the company to acquire 1,73,84,000 equity shares of the company representing 7.89 percent of the paid-up equity share capital at an agreed price of Rs 0.80 per equity share along with control over the company.

  • Six Times Failed Revision Hip Replacement Surgery of a Ghana patient performed successfully at Krishna Shalby Hospital, Ahmedabad by World-renowned Joint Replacement Surgeon Dr Vikram Shah – Primex News Network

    Six Times Failed Revision Hip Replacement Surgery of a Ghana patient performed successfully at Krishna Shalby Hospital, Ahmedabad by World-renowned Joint Replacement Surgeon Dr Vikram Shah – Primex News Network

    Shalby Team of Doctors sitting from right to left Dr Vikram Shah, Dr J A Pachore, Dr Amish Kshtriya. Standing – Dr Pranay Gujjar

    May 20: A six times failed hip replacement surgery of a Ghana patient was successfully performed by Dr Vikram Shah, world-renowned joint replacement surgeon, at Krishna Shalby Hospital in Ahmedabad. Besides Dr Vikram Shah, the team of Shalby’s surgeons for this rare surgery included Dr J A Pachore, Director, Hip Surgery, Dr Amish Kshatriya, Senior Joint Replacement Surgeon and Dr Pranay Gujjar, Joint Replacement Surgeon. Mrs Nansata Salifu from Bolgatanga town in Ghana is 65 years old. Mother of four, she is a retired midwife. Her husband is a financial economist. After a fall in December 2016 in which she suffered hip fracture, Mrs Salifu was operated for hip replacement for the first time in early 2017 in Bawku in Ghana, but it got infected.

    Then she sought treatment from another hospital in Kumasi, a large city of Ghana. However, this surgery too was a failure. Through the course of next two and a half years she endured a series of five failed hip replacement surgeries at the same hospital, which were one failure after another. In total, Mrs Salifu underwent six failed hip replacement surgeries in Ghana. Her condition had been worsening with each repeated surgery.

    Hip replacement is a surgery in which the damaged cartilage and bone is removed from the hip joint and replaced with artificial components. At times, hip replacement implants can wear out for various reasons and may need to be replaced with the help of a revision hip replacement surgery. However, this usually happens after 15-20 years of surgery.

    But this was not the case in Mrs Salifu’s case. In her case the cause was recurrent hip joint dislocation. Her hip was dislocated after six failed surgeries with almost 3 cm shortening of the leg. She had intense pain, walked with limp and shortening of leg. Her movement was severely restricted and she had intense pain in her hip. Her quality of life had suffered a lot because of this problem, and she had problems in carrying out even her daily chores.

    Revision hip replacement is normally a more challenging and complex procedure than the first surgery, and her accident and repeated failed surgeries had made this even more difficult and challenging.

    Dr Vikram Shah says, “We revised her acetabulum (socket of the hip bone in which the femur fits) with special instrumentation with no bone loss. Larger size cup and screws were used to fix the socket and special kind of plastic liner was used to prevent future dislocation. Revision surgery sometimes also requires bone grafting, for which we need large amount of bone. At Shalby we have a bone bank for this. She was kept on bed rest for 3 weeks for healing. After this, she was made to walk with walker support. And after six weeks she could walk without limp, shortening of leg and pain.”

    Mrs Salifu’s daughter says, “My mother had undergone several failed surgeries, and then we were referred Dr Vikram Shah and Shalby Hospital. Her surgery here has been a success now and she can walk again. Our whole family is very happy at this. I thank Dr Vikram Shah and Krishna Shalby Hospital for this.”

    This kind of surgery requires special instruments, special joint implant, well-equipped class 100 operation theatre set-up and above all a surgeon with extensive experience of performing revision hip replacement surgeries.

    Dr Vikram Shah says further, “At Shalby we perform almost 10,000 joint replacement surgeries in a year, which is highest in the world. Along with primary surgeries, we also get a large number of complex cases for revision surgeries from all across the world. About 250 of these are complex and revision hip replacement surgeries. Each case has a challenge of its own, but this particular case was unique and difficult as the patient had undergone surgeries six times already. We are happy she has been treated after five long years and can now lead a pain-free life.”

    Dr Vikram Shah is a world-renowned joint replacement surgeon and Founder Chairman & Managing Director of Shalby Hospitals, a chain of 11 hospitals spread across eight cities. He has played a prominent role in popularizing joint replacement surgery in India and has performed highest number of these surgeries in the world. His innovation of Zero Technique of joint replacement surgery has revolutionalized this surgery. This innovation reduced surgery time from many hours to just 8-10 minutes with added advantages of minimal blood loss, speedy recovery, near to nil infection rate and reduced hospital stay from 15 days to just 3-4 days. This has contributed in easing pain of millions suffering from joint pain, especially the elderly, improving their quality of life. Under his leadership, Shalby performs almost 10,000 joint replacement surgeries a year, which is highest in the world. Till now it has performed around 1,25,000 joint replacement surgeries, again highest in the world. Shalby is a preferred choice for primary and revision joint replacement as well as primary, revision and  complex orthopedic surgeries for patients not only from India but also from across the world.

  • Six Times Failed Revision Hip Replacement Surgery of a Ghana patient performed successfully at Krishna Shalby Hospital, Ahmedabad by World-renowned Joint Replacement Surgeon Dr Vikram Shah

    Six Times Failed Revision Hip Replacement Surgery of a Ghana patient performed successfully at Krishna Shalby Hospital, Ahmedabad by World-renowned Joint Replacement Surgeon Dr Vikram Shah

    Read Time:4 Minute, 24 Second

    Shalby Team of Doctors sitting from right to left Dr Vikram Shah, Dr J A Pachore, Dr Amish Kshtriya. Standing – Dr Pranay Gujjar

    May 20: A six times failed hip replacement surgery of a Ghana patient was successfully performed by Dr Vikram Shah, world-renowned joint replacement surgeon, at Krishna Shalby Hospital in Ahmedabad. Besides Dr Vikram Shah, the team of Shalby’s surgeons for this rare surgery included Dr J A Pachore, Director, Hip Surgery, Dr Amish Kshatriya, Senior Joint Replacement Surgeon and Dr Pranay Gujjar, Joint Replacement Surgeon. Mrs Nansata Salifu from Bolgatanga town in Ghana is 65 years old. Mother of four, she is a retired midwife. Her husband is a financial economist. After a fall in December 2016 in which she suffered hip fracture, Mrs Salifu was operated for hip replacement for the first time in early 2017 in Bawku in Ghana, but it got infected.

    Then she sought treatment from another hospital in Kumasi, a large city of Ghana. However, this surgery too was a failure. Through the course of next two and a half years she endured a series of five failed hip replacement surgeries at the same hospital, which were one failure after another. In total, Mrs Salifu underwent six failed hip replacement surgeries in Ghana. Her condition had been worsening with each repeated surgery.

    Hip replacement is a surgery in which the damaged cartilage and bone is removed from the hip joint and replaced with artificial components. At times, hip replacement implants can wear out for various reasons and may need to be replaced with the help of a revision hip replacement surgery. However, this usually happens after 15-20 years of surgery.

    But this was not the case in Mrs Salifu’s case. In her case the cause was recurrent hip joint dislocation. Her hip was dislocated after six failed surgeries with almost 3 cm shortening of the leg. She had intense pain, walked with limp and shortening of leg. Her movement was severely restricted and she had intense pain in her hip. Her quality of life had suffered a lot because of this problem, and she had problems in carrying out even her daily chores.

    Revision hip replacement is normally a more challenging and complex procedure than the first surgery, and her accident and repeated failed surgeries had made this even more difficult and challenging.

    Dr Vikram Shah says, “We revised her acetabulum (socket of the hip bone in which the femur fits) with special instrumentation with no bone loss. Larger size cup and screws were used to fix the socket and special kind of plastic liner was used to prevent future dislocation. Revision surgery sometimes also requires bone grafting, for which we need large amount of bone. At Shalby we have a bone bank for this. She was kept on bed rest for 3 weeks for healing. After this, she was made to walk with walker support. And after six weeks she could walk without limp, shortening of leg and pain.”

    Mrs Salifu’s daughter says, “My mother had undergone several failed surgeries, and then we were referred Dr Vikram Shah and Shalby Hospital. Her surgery here has been a success now and she can walk again. Our whole family is very happy at this. I thank Dr Vikram Shah and Krishna Shalby Hospital for this.”

    This kind of surgery requires special instruments, special joint implant, well-equipped class 100 operation theatre set-up and above all a surgeon with extensive experience of performing revision hip replacement surgeries.

    Dr Vikram Shah says further, “At Shalby we perform almost 10,000 joint replacement surgeries in a year, which is highest in the world. Along with primary surgeries, we also get a large number of complex cases for revision surgeries from all across the world. About 250 of these are complex and revision hip replacement surgeries. Each case has a challenge of its own, but this particular case was unique and difficult as the patient had undergone surgeries six times already. We are happy she has been treated after five long years and can now lead a pain-free life.”

    Dr Vikram Shah is a world-renowned joint replacement surgeon and Founder Chairman & Managing Director of Shalby Hospitals, a chain of 11 hospitals spread across eight cities. He has played a prominent role in popularizing joint replacement surgery in India and has performed highest number of these surgeries in the world. His innovation of Zero Technique of joint replacement surgery has revolutionalized this surgery. This innovation reduced surgery time from many hours to just 8-10 minutes with added advantages of minimal blood loss, speedy recovery, near to nil infection rate and reduced hospital stay from 15 days to just 3-4 days. This has contributed in easing pain of millions suffering from joint pain, especially the elderly, improving their quality of life. Under his leadership, Shalby performs almost 10,000 joint replacement surgeries a year, which is highest in the world. Till now it has performed around 1,25,000 joint replacement surgeries, again highest in the world. Shalby is a preferred choice for primary and revision joint replacement as well as primary, revision and  complex orthopedic surgeries for patients not only from India but also from across the world.

    About Post Author


    RNT Reporter


    dhaval.rntoday@gmail.com

    https://republicnewstoday.com

    The post Six Times Failed Revision Hip Replacement Surgery of a Ghana patient performed successfully at Krishna Shalby Hospital, Ahmedabad by World-renowned Joint Replacement Surgeon Dr Vikram Shah appeared first on Republic News Today.

  • Corporate Professionals managing to acquire 26% stake in Advik Capital for Rs 23.75 cr

    Corporate Professionals managing to acquire 26% stake in Advik Capital for Rs 23.75 cr

    Read Time:1 Minute, 18 Second

    New Delhi (India), May 20: Corporate Professionals Capital Private Limited is managing to acquire a significant stake in Advik Capital Limited (ACL), the company said in a regulatory filing on 18th May.

    According to the company filing, Corporate professionals managed to buy 5,72,50,253 equity shares with a face value of Re 1 each at a price of Rs 4.15 apiece amounting to Rs 23,75,88,550.

    The deal aggregates to 26 percent paid up equity share capital of the company. The Offer Price will be paid in cash, in accordance with the provisions of Regulation of the SEBI (SAST) Regulations.

    The filing also clarified that the purchase has been made on behalf of Mr. Vikas Garg and Ms Seema Garg (termed as Acquirers); and Ms Sukriti Garg (person acting in concert or ‘PAC’).

    Incorporated in year 1985, Advik Capital Limited is a non-banking finance company (NBFC) registered with the Reserve Bank of India (RBI).

    Mr. Virender Kumar Agarwal and Mr. Shakul Kumar Agarwal, the current members of the promoter and promoter group of the Advik Capital to sell their shares constituting 7.89 percent stake in the company, which triggered the open offer.

    On May 18, 2022, the Acquirers have entered into the special purchase agreement (SPA) with the sellers of the company to acquire 1,73,84,000 equity shares of the company representing 7.89 percent of the paid-up equity share capital at an agreed price of Rs 0.80 per equity share along with control over the company.

    About Post Author


    RNT Reporter


    dhaval.rntoday@gmail.com

    https://republicnewstoday.com

    The post Corporate Professionals managing to acquire 26% stake in Advik Capital for Rs 23.75 cr appeared first on Republic News Today.

  • Filling primary, preventive, and predictive care delivery gaps in India by reimagined ‘phygital’ health ecosystem

    Filling primary, preventive, and predictive care delivery gaps in India by reimagined ‘phygital’ health ecosystem

    Read Time:4 Minute, 17 Second

    • ‘Phygital’ ecosystem complements corporate wellness by filling a massive gap in preventive health screening as 59% of employees in India are stressed in everyday life [1]
    • ‘Phygital’ ecosystem is patient-friendly as it saves time and money for patients from traditional screening 
    • 12% of major illnesses in rural areas remain untreated mainly due to unavailability of diagnostic facilities [2] and ‘Phygital’ ecosystem helps in getting easy access to preventive screening 

    New Delhi (India), May 20: India has made reasonable progress in improving access to last-mile healthcare over the last decade. However, the improved access has not reached across the country equally because of the acute shortage of qualified professionals (fully trained doctors, lab technicians) and the lack of feasible and accessible healthcare delivery mechanisms. Out of the 140+ crore population in India, only 21.9 crore Ayushman Bharat Health Account (ABHA) IDs have been created. [3]

    In such a scenario, to fill the existing gaps in primary healthcare, which, in turn, fills the gaps in preventive healthcare, India Health Link (IHL) have introduced a first-of-its-kind connected ‘human-centric’ Phygital (physical+digital) screening ecosystem, which includes the award-winning ATM size ‘made in India’ Health Pod (‘hPod’) for zero assistance automated vitals screening. And the Health Pod also complements National Digital Health Mission (NDHM) as it creates personalised Health accounts and IDs in line with the ABHA account.

    “The ‘hPod’ offers a non-invasive digitally-integrated ecosystem that enables Primary, Preventive and Predictive Healthcare. This is a self-service, walk-in Health Pod wherein individuals can get their screening done for 22+ health vital parameters including BP, Weight, SpO2, BMI, BMC, Pulse, Temperature, and ECG within 5 minutes followed by an instant report, without any paramedic assistance. The ‘phygital’ ecosystem provides a physical experience of preventive health check-ups supported by its digital interface that maintains users’ health records and provides immediate consultation with certified health professionals based on instant test results. The hPod is HIPPA compliant and features medical devices certified by US FDA, CE, and Neumetric,” says Dr Satyender Goel, Founder & CEO, India Health Link (IHL). 

    Dr Swadeep Srivastava Co-Founder & President, of India Health Link (IHL), said, “Despite being home to over 70% of Indians, rural and non-metro areas face a significant shortage of high-quality diagnostic services, especially preventive diagnosis. And we wish to promote preventive care culture to reduce the NCD burden in India by enabling doctors’ clinics, nursing homes, corporate workplaces, and communities across India with this ‘phygital’ ecosystem – health Pod (‘hPod’). We believe that this ‘phygital’ ecosystem, can address the gaps in primary and preventive healthcare delivery, and simultaneously fill them, making it feasible, affordable and accessible to all Indians irrespective of their socio-economic status.”

     Dr Goel further elaborates on the three-prong approach to how the ‘phygital’ ecosystem of IHL is going to fill the primary, preventive, and predictive healthcare delivery gaps in India.

    First, the IHL ‘phygital’ ecosystem complements corporate wellness by filling a massive gap in preventive health screening. Recently, we have seen that due to the lack of preventive screening culture in the Indian healthcare ecosystem, many young professionals associated with corporates have succumbed to cardiac arrest. A Marsh India report reveals that 59% of employees in India are stressed in everyday life. In the absence of preventive screening, it is often too late for employees when they discover the stemming medical conditions that have led to non-communicable diseases (NCDs).

    Second, the IHL ‘phygital’ ecosystem is turning out to be patient-friendly as it saves time and money the patients used to spend on traditional diagnosis because, in modern healthcare, the role of early detection and correct diagnosis cannot be overstated. About 70% of all clinical decisions are taken based on diagnostic tests, which require a highly evolved digital platform. To overcome the screening hurdles, the health Pod is being installed in doctors’ clinics and nursing homes to make the preventive screening services feasible and accessible followed by an instant report.

    And third, the IHL ‘phygital’ ecosystem is turning out to be a boon for community settings, especially for rural India, because a significant proportion of India’s population (~70%) lives in rural areas where screening is seldom carried out. In rural India, 12% of major illnesses remain untreated mainly due to the unavailability of diagnostic facilities and the ‘Phygital’ ecosystem helps in getting easy access to preventive screening. Today, nearly 60 per cent of all deaths in India are due to NCDs. [4] One of the underlying reasons for the upsurge of NCDs is the lack of preventive and predictive screening. But the IHLs ‘phygital’ ecosystem is poised to fill the massive gap by providing a cost-effective screening facility followed by an instant report delivery mechanism.

    What differentiates IHLs Health Pod from its counterparts is its unique ‘phygital’ ecosystem. The blending of the physical and digital models has made ‘phygital’, making it portable and user-friendly. This ‘phygital’ model seems to be promising from the Indian perspective as it will be instrumental in filling the emanating preventive and primary healthcare delivery gaps in India.

    About Post Author


    RNT Reporter


    dhaval.rntoday@gmail.com

    https://republicnewstoday.com

    The post Filling primary, preventive, and predictive care delivery gaps in India by reimagined ‘phygital’ health ecosystem appeared first on Republic News Today.

  • Breast-Milk Donation Awareness Summit held on World Human Milk Donation Day by NeoLacta Lifesciences

    Breast-Milk Donation Awareness Summit held on World Human Milk Donation Day by NeoLacta Lifesciences

    Read Time:3 Minute, 46 Second

    New Delhi (India), May 20: In an initiative to spread awareness about the ‘Importance of Breast Milk Donation, NeoLacta Lifesciences under their ‘Save Babies’ Initiative on ‘World Human Milk Donation Day 2022’, organized a virtual summit bringing together medical professionals, parents and donor moms.

    For more than a decade, 19th May has been celebrated annually as the internationally designated World Day of Human Milk Donation. Originating in Brazil in 2004 as a national event, the day was created to promote the importance of donating human milk to save lives of premature and sick infants. It is now marked by milk banks and human milk donation supporters globally and with over 750 human milk banks in 66 countries there are thousands of donor mothers to thank! It is estimated that more than 800,000 infants receive donor human milk each year which suggests that well over 1 million litres of milk are donated annually in support of optimal infant nutrition and breastfeeding.

    Dr. Geetika Gangwani, Lactation consultant, Save Babies initiative stated, “I believe Breast-Milk donation is the most precious of all donations as it helps saves lives of little babies and build a healthier future generation. Screened and pasteurised donated breast milk is given to preterm and sick babies who don’t have access to their mother’s own milk.  Even World Health Organization (WHO) recommends pasteurised donor human milk as the next best option in absence of a mother’s own milk.

    SaveBabies is a unique initiative started by NeoLacta Lifesciences, for premature and sick babies who don’t have access to their own mother’s milk, by providing optimum nutrition through screened and pasteurised donor milk. Save Babies partners with mothers and the medical community to generate awareness and encourage healthy mothers to donate their excess milk, ensuring intact survival and a healthy future for these little ones. Through this initiative complete support is provided to the donor mothers by guiding, counselling, testing for infections, logistics as well as providing storage bottles for expression.

    Dr Dipti Shah, Gynaecologist, Me & Mummy Hospital, Ahmedabad informed “Exclusive Human Milk Diet has immense benefits beyond just nutrition. Immunological and anti-infective components are one of the unique benefits of human milk which ensure protection against viral, bacterial, and fungal infections in infants. This is even more important for premature babies who have immature organs and immune systems”.

    “When I was donating my excess milk while breastfeeding my own child, it was the greatest thing to wonder who was going to receive my donation. It could be a future engineer who might build the next tallest building to a researcher who finds the cure for cancer”, stated Dr Adithi, Physiotherapist, mother to 3 months old baby and a donor with Save Babies initiative.

    According to Dr. Ramani Ranjan Paediatrician & Neonatologist, Apollo Cradle Greater Noida, “I believe more and more healthcare professionals should come forward and support the initiative of ensuring access to an exclusive human milk for new born infants, especially those with a birthweight less than or equal to 1,250 grams because of the overwhelming evidence supporting human milk nutrition for these tiny ones”.

    According to the World Health Organization over 1million babies die every year from complications associated with prematurity, and it is the leading cause of death for infants under 4 weeks old. Availability of donor human milk can immensely impact the health outcomes for these fragile infants who don’t have access to their mother’s own milk.

    Dr Vikram Reddy, Chief Scientific Officer, NeoLacta Lifesciences, underlined, “We believe healthcare professionals should come forward and support the initiative by educating their patients about excess milk donation and usage of exclusive human milk diet for new-born infants, especially those born early and/or with low birth weight as there is clear evidence suggesting that exclusive human milk nutrition is life saving for these tiny babies”.

    The way forward is to encourage breastmilk donation as a norm rather than an exception by  developing a community across the country to support, educate and create awareness about the importance of accepting and donating human milk. The vision is to ensure that all hospitals across the country should have access to screened and pasteurised donor human milk. Doctors, lactation experts, parents, clinical fraternity, community health workers and family support organisations should come together to spread awareness about the importance of human milk donation.

    Issued in public interest by NeoLacta Lifesciences (India’s only ISO 22000:2018 and GMP certified human milk facility).

    About Post Author


    RNT Reporter


    dhaval.rntoday@gmail.com

    https://republicnewstoday.com

    The post Breast-Milk Donation Awareness Summit held on World Human Milk Donation Day by NeoLacta Lifesciences appeared first on Republic News Today.

  • Lincoln Pharma reports Best-Ever Results in a Financial Year; Reports Highest Revenue, EBIDTA, Net Profit in FY22 – Primex News Network

    Lincoln Pharma reports Best-Ever Results in a Financial Year; Reports Highest Revenue, EBIDTA, Net Profit in FY22 – Primex News Network

    Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd

    Company recommends 15% dividend, Rs. 1.50 per share for FY 22

    Ahmedabad, May 20, 2022:

     

     

    FY22 Results Highlights:– (Standalone)

    ·         Net Profit Reports Y-o-Y growth of 11.42% to Rs. 69.36 crore;

    ·         Net Revenues from operations reports Y-o-Y growth of 11.63% to Rs. 472.08 crore;

    ·         EBITDA reports Y-o-Y growth of 13.67% to Rs. 105.47 crore.

    Business Highlights:-

    ·         FOB Value of exports for FY22 reports Rs. 266.18 crore;

    ·         Capital investment using internal source of fund for acquisition of cephalosporin plant (including capacity expansion) for Rs. 30 crore;

    ·         CRISIL has upgraded its ratings on the company’s bank facilities to ‘CRISIL A/Stable/CRISIL A1’;

    ·         Company achieved strong liquidity position supported by healthy cash accruals and become Net Debt free.

     

    Financial Highlights (Standalone)

                                                                                 (Amount in Cr except EPS)

    Particulars FY22 FY21 Y-O-Y
    Net Revenue from Operations 472.08 422.91 11.63%
    EBITDA 105.47 92.78 13.67%
    Profit before Tax 95.93 83.67 14.65%
    Net Profit 69.36 62.25 11.42%
    E.P.S (Rs.) 34.63 31.08 11.42%

     

    Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported its Best-ever results in a financial year with highest – Revenue, EBITDA and Net Profit for the FY ended March 2022. Company has recommended a dividend of 15%, Rs. 1.50 per share on the face value of Rs. 10 per share for the FY 2021-22.

    Company reported net profit of Rs. 69.36 crore for FY22 as against net profit of Rs. 62.25 crore in the corresponding period last year, growth of 11.42%. Net revenue from operations for FY22 was reported at Rs. 472.08 crore, higher by 11.63% over previous fiscal’s same period revenue of Rs. 422.91 crore. Company reported EBITDA of Rs. 105.47 crore in FY22, rise of 13.67% as compared to EBITDA of Rs. 92.78 crore in FY21. EPS for FY22 was reported at Rs. 34.63 per share.

    Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “We feel proud to inform all our stakeholders that the company is progressing well on its long-term growth roadmap. Company has reported excellent numbers for FY 2022 with highest Revenue, EBITDA and Net Profit reported on a yearly basis. With a robust performance, the company has recommended a dividend of Rs. 1.50 per share. Company’s expansion plans for Cephalosporin products and foray in EU and Australian markets are also progressing well. Company is growing strength to strength, delivering robust operational and

    financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue and expect to get further boost in coming years.”

    CRISIL Ratings has upgraded its ratings on the bank facilities of Lincoln Pharmaceuticals Ltd to ‘CRISIL A/Stable/CRISIL A1’ from CRISIL A-/Positive/CRISIL A2+. CRISIL report further states that, “The rating upgrade reflects the Lincoln group’s improved business profile and the continued consolidation in the financial risk profile. Over the medium term, the group is expected to maintain its growth trajectory and healthy margin. This shall be supported by addition of Cephalosporin which has potential to add around 30% to the topline over next three fiscals. Further, the group’s European market foray shall provide additional fillip to the business profile.”

     

     

    Financial Overview – Lincoln Pharmaceuticals FY 12 to FY22

     

    Year Revenue EBITDA Net Profit EPS ROCE
    FY 22 472.08 105.47 69.36 34.63 21.93%
    FY 12 175.5 16.9 5.12 3.14 10%
    10 Yrs CAGR 10.40% 20.09% 29.77% 27.13% 8.17%

    During the last 10 years from FY12 to FY22, Lincoln Pharmaceuticals Ltd has delivered a robust 29.77% plus CAGR in Net profits, 20.09% in EBITDA and 10.40% in Revenue. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, free cash/liquid investments, no term debt and healthy return ratios. Rating agency ICRA too has reaffirmed the company’s long-term and short-term bank facilities to A and A1 respectively.

    Update on Cephalosporin Expansion – In September 2021, company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products. Capital investment using internal source of fund for acquisition of cephalosporin plant (including capacity expansion) for Rs. 30 crore. The plant is expected to contribute sales of around Rs. 150 crore in the next 3 years. The plant will cater to all the Cephalosporin products i.e. Tablet, Capsule, Dry syrup and Injectable.

    Export business of the company has shown strong growth over the years. It currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia. TGA – Australia and EU GMP approvals will strengthen the company’s presence and expand its network to 90 plus countries. FOB Value of Exports for FY22 reports of Rs. 266.18 crore.

    Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP, TGA – Australia and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. To complement the company’s strong presence in the acute segment, the company is also building a portfolio in lifestyle and chronic segments especially dermatology, gastro and pain management. Company has filed 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.

    Lincoln Pharmaceuticals Limited: https://www.lincolnpharma.com/

    Providing Affordable and Innovative medicines for healthier lives.

    Lincoln Pharmaceuticals Ltd is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

    Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create “Healthcare for All”.

    Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EU GMP, WHO-GMP and ISO-9001: 2015. Recently the company has also received an approval from Australia’s medicines and medical devices regulator – Therapeutic Goods Administration (TGA). TGA and EU GMP approvals will further strengthen the company’s presence in the export market from 60 plus countries to over 90 plus countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

    Company’s key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

    Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country. Company has a wide national distribution network through 21+ Super Stockist and over 50,000 retailers in 26 states across India.

    Going green, company has also set up a new Solar Plant of 1 MW at factory’s rooftop in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

  • The Dynamix Group aims to launch close to 1.1 mn sq. ft of projects in 2022, in addition to its ongoing works of 2.2 million sq. ft in Thane and Mumbai – Primex News Network

    The Dynamix Group aims to launch close to 1.1 mn sq. ft of projects in 2022, in addition to its ongoing works of 2.2 million sq. ft in Thane and Mumbai – Primex News Network

    ~The group has already delivered over 30 million sq. ft to its customers over 5 decades in business~

     New Delhi (India), May 20: The Dynamix Group is set to launch 3 new projects in Mumbai in 2022, in Sahar, Goregaon and Malad, expecting to spend over INR 1050 crs over the course of the development of these projects, which would be developed over the next 3-4 years. The FY21-22 brought on a lot of sales, as the people started moving back to the cities for work and education.

    The Dynamix group in the Mumbai Metropolitan Region and Goa, they accomplished sales worth Rs 330.6 crs in FY20-21 (despite losing the first 2 quarters to the lockdown). In FY21-22, their sales numbers more than doubled (an increase of 129%), to Rs 756.4 crs across diverse projects and joint ventures.

    As a company, the Dynamix Group has always been focused on well-designed and thoughtful residential and commercial developments, and they reinforced this commitment through their launches immediately post the first wave of the pandemic, and till date. Their performance reflected a strong acceptance of their product and thesis.

    The projects combined contributed to sales worth INR 756 crs for the financial year 2021-22. Thus far the Dynamix Group has delivered over 30 million sq. ft. of real estate to date and are currently developing projects spread over 3.5 million sq. ft. in Mumbai, Thane and Goa.With multiple upcoming projects which will add great value to the real estate market over the course of the next year. These projects are situated in Goregaon, Malad and Sahar respectively and aggregate to almost 1.1 million sq. ft. of development.

    Speaking on the developments, Jay Goenka, Director, Dynamix Group said “We are very excited about our sales growth in FY 21-22 and our upcoming project launches. We believe that our keen focus on building spaces that deliver functionality, convenience, and quality lifestyles will stand us in good stead for them. These planned launches continue to be the realization of our strategy to grow through the development of high quality, yet affordable homes and commercial spaces across Mumbai.”

    This will be funded by a combination of equity, debt and subsequently sales receipts once the projects are launched. In addition to this the group will continue investing in maturing its land holdings to continue building its pipeline for launch and further sales for the subsequent financial years.

    Through these upcoming projects the Dynamix Group hopes to continue to cater to the seeker of high quality homes and spaces.

    The Dynamix Group is renowned for its thoughtful and well-designed residential and commercial developments in Mumbai and the Mumbai Metropolitan Region. The Group’s residential developments of Gokuldham and Yashodham in Goregaon East alleviated the acute shortage of affordable housing faced by the middle and lower income groups in the suburban areas of Mumbai. This served as a springboard for further projects in the suburbs, in areas such as Vasant Vihar in Thane West, Shristiin Mira Road, Upvan Complex in Upper Govind Nagar, Gokuldham in Goregaon East, and Panchsheel Enclave in Kandivali West, toname a few. Dynamix Groupbrings a 50 year legacy of high quality development with over 30 million sq. feet delivered to over 30,000 happy families.

    http://dynamixgroup.co.in/

  • The Dynamix Group aims to launch close to 1.1 mn sq. ft of projects in 2022, in addition to its ongoing works of 2.2 million sq. ft in Thane and Mumbai

    The Dynamix Group aims to launch close to 1.1 mn sq. ft of projects in 2022, in addition to its ongoing works of 2.2 million sq. ft in Thane and Mumbai

    Read Time:2 Minute, 47 Second

    ~The group has already delivered over 30 million sq. ft to its customers over 5 decades in business~

     New Delhi (India), May 20: The Dynamix Group is set to launch 3 new projects in Mumbai in 2022, in Sahar, Goregaon and Malad, expecting to spend over INR 1050 crs over the course of the development of these projects, which would be developed over the next 3-4 years. The FY21-22 brought on a lot of sales, as the people started moving back to the cities for work and education.

    The Dynamix group in the Mumbai Metropolitan Region and Goa, they accomplished sales worth Rs 330.6 crs in FY20-21 (despite losing the first 2 quarters to the lockdown). In FY21-22, their sales numbers more than doubled (an increase of 129%), to Rs 756.4 crs across diverse projects and joint ventures.

    As a company, the Dynamix Group has always been focused on well-designed and thoughtful residential and commercial developments, and they reinforced this commitment through their launches immediately post the first wave of the pandemic, and till date. Their performance reflected a strong acceptance of their product and thesis.

    The projects combined contributed to sales worth INR 756 crs for the financial year 2021-22. Thus far the Dynamix Group has delivered over 30 million sq. ft. of real estate to date and are currently developing projects spread over 3.5 million sq. ft. in Mumbai, Thane and Goa.With multiple upcoming projects which will add great value to the real estate market over the course of the next year. These projects are situated in Goregaon, Malad and Sahar respectively and aggregate to almost 1.1 million sq. ft. of development.

    Speaking on the developments, Jay Goenka, Director, Dynamix Group said “We are very excited about our sales growth in FY 21-22 and our upcoming project launches. We believe that our keen focus on building spaces that deliver functionality, convenience, and quality lifestyles will stand us in good stead for them. These planned launches continue to be the realization of our strategy to grow through the development of high quality, yet affordable homes and commercial spaces across Mumbai.”

    This will be funded by a combination of equity, debt and subsequently sales receipts once the projects are launched. In addition to this the group will continue investing in maturing its land holdings to continue building its pipeline for launch and further sales for the subsequent financial years.

    Through these upcoming projects the Dynamix Group hopes to continue to cater to the seeker of high quality homes and spaces.

    The Dynamix Group is renowned for its thoughtful and well-designed residential and commercial developments in Mumbai and the Mumbai Metropolitan Region. The Group’s residential developments of Gokuldham and Yashodham in Goregaon East alleviated the acute shortage of affordable housing faced by the middle and lower income groups in the suburban areas of Mumbai. This served as a springboard for further projects in the suburbs, in areas such as Vasant Vihar in Thane West, Shristiin Mira Road, Upvan Complex in Upper Govind Nagar, Gokuldham in Goregaon East, and Panchsheel Enclave in Kandivali West, toname a few. Dynamix Groupbrings a 50 year legacy of high quality development with over 30 million sq. feet delivered to over 30,000 happy families.

    http://dynamixgroup.co.in/

    About Post Author


    RNT Reporter


    dhaval.rntoday@gmail.com

    https://republicnewstoday.com

    The post The Dynamix Group aims to launch close to 1.1 mn sq. ft of projects in 2022, in addition to its ongoing works of 2.2 million sq. ft in Thane and Mumbai appeared first on Republic News Today.

  • Lincoln Pharma reports Best-Ever Results in a Financial Year; Reports Highest Revenue, EBIDTA, Net Profit in FY22

    Lincoln Pharma reports Best-Ever Results in a Financial Year; Reports Highest Revenue, EBIDTA, Net Profit in FY22

    Read Time:7 Minute, 11 Second

    Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd

    Company recommends 15% dividend, Rs. 1.50 per share for FY 22

    Ahmedabad, May 20, 2022:

     

     

    FY22 Results Highlights:– (Standalone)

    ·         Net Profit Reports Y-o-Y growth of 11.42% to Rs. 69.36 crore;

    ·         Net Revenues from operations reports Y-o-Y growth of 11.63% to Rs. 472.08 crore;

    ·         EBITDA reports Y-o-Y growth of 13.67% to Rs. 105.47 crore.

    Business Highlights:-

    ·         FOB Value of exports for FY22 reports Rs. 266.18 crore;

    ·         Capital investment using internal source of fund for acquisition of cephalosporin plant (including capacity expansion) for Rs. 30 crore;

    ·         CRISIL has upgraded its ratings on the company’s bank facilities to ‘CRISIL A/Stable/CRISIL A1’;

    ·         Company achieved strong liquidity position supported by healthy cash accruals and become Net Debt free.

     

    Financial Highlights (Standalone)

                                                                                 (Amount in Cr except EPS)

    Particulars FY22 FY21 Y-O-Y
    Net Revenue from Operations 472.08 422.91 11.63%
    EBITDA 105.47 92.78 13.67%
    Profit before Tax 95.93 83.67 14.65%
    Net Profit 69.36 62.25 11.42%
    E.P.S (Rs.) 34.63 31.08 11.42%

     

    Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported its Best-ever results in a financial year with highest – Revenue, EBITDA and Net Profit for the FY ended March 2022. Company has recommended a dividend of 15%, Rs. 1.50 per share on the face value of Rs. 10 per share for the FY 2021-22.

    Company reported net profit of Rs. 69.36 crore for FY22 as against net profit of Rs. 62.25 crore in the corresponding period last year, growth of 11.42%. Net revenue from operations for FY22 was reported at Rs. 472.08 crore, higher by 11.63% over previous fiscal’s same period revenue of Rs. 422.91 crore. Company reported EBITDA of Rs. 105.47 crore in FY22, rise of 13.67% as compared to EBITDA of Rs. 92.78 crore in FY21. EPS for FY22 was reported at Rs. 34.63 per share.

    Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “We feel proud to inform all our stakeholders that the company is progressing well on its long-term growth roadmap. Company has reported excellent numbers for FY 2022 with highest Revenue, EBITDA and Net Profit reported on a yearly basis. With a robust performance, the company has recommended a dividend of Rs. 1.50 per share. Company’s expansion plans for Cephalosporin products and foray in EU and Australian markets are also progressing well. Company is growing strength to strength, delivering robust operational and

    financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue and expect to get further boost in coming years.”

    CRISIL Ratings has upgraded its ratings on the bank facilities of Lincoln Pharmaceuticals Ltd to ‘CRISIL A/Stable/CRISIL A1’ from CRISIL A-/Positive/CRISIL A2+. CRISIL report further states that, “The rating upgrade reflects the Lincoln group’s improved business profile and the continued consolidation in the financial risk profile. Over the medium term, the group is expected to maintain its growth trajectory and healthy margin. This shall be supported by addition of Cephalosporin which has potential to add around 30% to the topline over next three fiscals. Further, the group’s European market foray shall provide additional fillip to the business profile.”

     

     

    Financial Overview – Lincoln Pharmaceuticals FY 12 to FY22

     

    Year Revenue EBITDA Net Profit EPS ROCE
    FY 22 472.08 105.47 69.36 34.63 21.93%
    FY 12 175.5 16.9 5.12 3.14 10%
    10 Yrs CAGR 10.40% 20.09% 29.77% 27.13% 8.17%

    During the last 10 years from FY12 to FY22, Lincoln Pharmaceuticals Ltd has delivered a robust 29.77% plus CAGR in Net profits, 20.09% in EBITDA and 10.40% in Revenue. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, free cash/liquid investments, no term debt and healthy return ratios. Rating agency ICRA too has reaffirmed the company’s long-term and short-term bank facilities to A and A1 respectively.

    Update on Cephalosporin Expansion – In September 2021, company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products. Capital investment using internal source of fund for acquisition of cephalosporin plant (including capacity expansion) for Rs. 30 crore. The plant is expected to contribute sales of around Rs. 150 crore in the next 3 years. The plant will cater to all the Cephalosporin products i.e. Tablet, Capsule, Dry syrup and Injectable.

    Export business of the company has shown strong growth over the years. It currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia. TGA – Australia and EU GMP approvals will strengthen the company’s presence and expand its network to 90 plus countries. FOB Value of Exports for FY22 reports of Rs. 266.18 crore.

    Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP, TGA – Australia and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. To complement the company’s strong presence in the acute segment, the company is also building a portfolio in lifestyle and chronic segments especially dermatology, gastro and pain management. Company has filed 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.

    Lincoln Pharmaceuticals Limited: https://www.lincolnpharma.com/

    Providing Affordable and Innovative medicines for healthier lives.

    Lincoln Pharmaceuticals Ltd is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

    Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create “Healthcare for All”.

    Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EU GMP, WHO-GMP and ISO-9001: 2015. Recently the company has also received an approval from Australia’s medicines and medical devices regulator – Therapeutic Goods Administration (TGA). TGA and EU GMP approvals will further strengthen the company’s presence in the export market from 60 plus countries to over 90 plus countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

    Company’s key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

    Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country. Company has a wide national distribution network through 21+ Super Stockist and over 50,000 retailers in 26 states across India.

    Going green, company has also set up a new Solar Plant of 1 MW at factory’s rooftop in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

    About Post Author


    RNT Reporter


    dhaval.rntoday@gmail.com

    https://republicnewstoday.com

    The post Lincoln Pharma reports Best-Ever Results in a Financial Year; Reports Highest Revenue, EBIDTA, Net Profit in FY22 appeared first on Republic News Today.